Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs

JAMA. 2018 Jun 5;319(21):2167-2168. doi: 10.1001/jama.2018.3414.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / economics
  • Antineoplastic Agents* / therapeutic use
  • Cost Control / legislation & jurisprudence
  • Drug Costs*
  • Drug Discovery
  • Drug Industry / legislation & jurisprudence*
  • Humans
  • Insurance, Pharmaceutical Services
  • Medicare*
  • Molecular Targeted Therapy*
  • Prescription Fees*
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents